Reaction

Iridocyclitis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,086 reports · 60 co-occurring drugs

As of the last recalculation, Iridocyclitis appears in 3,086 FAERS reports alongside 60 co-occurring drug terms. The strongest observed disproportionality signal is FARICIMAB (PRR 207.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Faricimab	231	207.7	213.8
Aflibercept	165	37.6	37.8
Adalimumab-Fkjp	201	31.2	31.4
Prednisolone Acetate	45	29.8	29.9
Adalimumab-Aaty	189	28.6	28.7
Zoledronic Acid	161	28.5	28.6
Adalimumab-Adaz	197	26.8	26.9
Ranibizumab	99	26.0	26.0
Brimonidine Tartrate	61	23.5	23.6
Moxifloxacin Hydrochloride	55	18.6	18.7
Vemurafenib	32	18.1	18.2
Moxifloxacin	36	17.4	17.5
Timolol	29	16.3	16.4
Brinzolamide	19	14.8	14.9
Dabrafenib	44	14.3	14.3
Dorzolamide Hydrochloride And Timolol Maleate	16	13.7	13.7
Atropine	16	13.1	13.1
Encorafenib	17	11.6	11.7
Trametinib	41	11.6	11.6
Atropine Sulfate	18	11.3	11.3
Ipilimumab	66	10.5	10.5
Ganciclovir	13	8.6	8.6
Ganciclovir Sodium	13	8.3	8.3
Timolol Maleate	12	8.2	8.2
Rifampicin	12	8.0	8.0
Latanoprost	57	7.8	7.8
Oseltamivir	8	6.8	6.8
Travoprost	8	6.3	6.3
Isoniazid	14	5.9	5.9
Pyrazinamide	8	5.8	5.8
Bevacizumab	97	5.4	5.4
Nivolumab	74	5.3	5.3
Nevirapine	7	5.2	5.2
Tobramycin Solution	9	5.1	5.1
Posaconazole Delayed-Release	8	4.9	4.9
Tobramycin Sulfate	9	4.9	4.9
Baricitinib	7	4.9	4.9
Alendronate Sodium Tablet	13	4.7	4.7
Clarithromycin	24	4.7	4.7
Golimumab	59	4.7	4.7
Dexamethasone Sodium Phosphate	7	4.7	4.7
Voriconazole Injection	14	4.4	4.4
Amphotericin B	8	4.3	4.3
Etanercept	346	4.3	4.3
Erlotinib	6	4.2	4.2
Darunavir	9	4.0	4.0
Erlotinib Hydrochloride	7	3.8	3.8
Bimatoprost	16	3.8	3.8
Dolutegravir Sodium	5	3.7	3.7
Rifampin	8	3.7	3.7
Secukinumab	85	3.6	3.6
Tofacitinib Citrate	7	3.6	3.6
Ado-Trastuzumab Emtansine	4	3.2	3.2
Pembrolizumab	43	2.8	2.8
Sofosbuvir	7	2.4	2.4
Abemaciclib	7	2.4	2.4
Olaparib	6	1.9	1.9
Atezolizumab	11	1.9	1.9
Apalutamide	3	1.7	1.7
Lifitegrast	4	1.7	1.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.